IMPACT OF KP.2 BNT162B2 COVID-19 VACCINE ON HEALTH-RELATED QUALITY OF LIFE AMONG SYMPTOMATIC U.S. ADULTS WITH SARS-COV-2 DURING THE 2024-2025 RESPIRATORY SEASON
Author(s)
Alon Yehoshua, PharmD1, Rachel Brathwaite, PhD2, Joseph C. Cappelleri, MPH, MS, PhD1, Tianyan Hu, PhD1, Manuela Di Fusco, PhD1, Meghan Gavaghan, MPH1, Xiaowu Sun, PhD3;
1Pfizer, New York, NY, USA, 2CVS Health, Wellesley, MA, USA, 3CVS Health, Woonsocket, RI, USA
1Pfizer, New York, NY, USA, 2CVS Health, Wellesley, MA, USA, 3CVS Health, Woonsocket, RI, USA
Presentation Documents
OBJECTIVES: This research evaluated the effect of the Pfizer-BioNTech BNT162b2 KP.2 COVID-19 vaccine on health-related quality of life (HRQoL) during the first week of infection among test-confirmed symptomatic adults in the 2024-2025 respiratory season.
METHODS: Adults testing positive for SARS-CoV-2 at a national pharmacy chain between October 24, 2024, and April 15, 2025, were enrolled (CT.gov: NCT05160636). Participants provided consent within 5 days of testing and completed a self-reported online survey capturing demographics, clinical history, and vaccination status. HRQoL was measured using EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility index (UI UI; range -0.573 to 1, higher scores indicate better health), collected daily post-enrollment and retrospectively recalled for the pre-infection period. Regression-based least-squares mean estimates for changes from pre-infection UI were calculated and compared between KP.2 vaccinated patients and unvaccinated patients. A running average of means was computed for each survey time point to estimate the average daily UI from symptom onset through a median of 7 days post-infection.
RESULTS: Among 608 participants, 106 (17.4%) received the 2024-2025 KP.2 vaccine, and 502 (82.4%) were unvaccinated. The mean age was 45.8 years; 76.5% were female; 53.6% used antiviral treatment; and 57.7% had ≥1 comorbidity. Among vaccinated participants, the mean (SD) time since vaccination was 167.2 (87.6) days. The median time from symptom onset to enrollment was 4 days. At the third survey (median of 7 days from symptom onset), the running average change in UI from pre-infection for the vaccinated group was 0.026 (SE: 0.012, P=0.029) lower than the unvaccinated group, indicating less HRQoL loss among vaccinated individuals.
CONCLUSIONS: BNT162b2 KP.2 vaccine was associated with improved HRQoL in the first week of COVID-19 infection during the 2024-2025 respiratory season. These results reinforce the benefits of COVID-19 vaccination and underscore the importance of remaining up to date with vaccine recommendations.
METHODS: Adults testing positive for SARS-CoV-2 at a national pharmacy chain between October 24, 2024, and April 15, 2025, were enrolled (CT.gov: NCT05160636). Participants provided consent within 5 days of testing and completed a self-reported online survey capturing demographics, clinical history, and vaccination status. HRQoL was measured using EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility index (UI UI; range -0.573 to 1, higher scores indicate better health), collected daily post-enrollment and retrospectively recalled for the pre-infection period. Regression-based least-squares mean estimates for changes from pre-infection UI were calculated and compared between KP.2 vaccinated patients and unvaccinated patients. A running average of means was computed for each survey time point to estimate the average daily UI from symptom onset through a median of 7 days post-infection.
RESULTS: Among 608 participants, 106 (17.4%) received the 2024-2025 KP.2 vaccine, and 502 (82.4%) were unvaccinated. The mean age was 45.8 years; 76.5% were female; 53.6% used antiviral treatment; and 57.7% had ≥1 comorbidity. Among vaccinated participants, the mean (SD) time since vaccination was 167.2 (87.6) days. The median time from symptom onset to enrollment was 4 days. At the third survey (median of 7 days from symptom onset), the running average change in UI from pre-infection for the vaccinated group was 0.026 (SE: 0.012, P=0.029) lower than the unvaccinated group, indicating less HRQoL loss among vaccinated individuals.
CONCLUSIONS: BNT162b2 KP.2 vaccine was associated with improved HRQoL in the first week of COVID-19 infection during the 2024-2025 respiratory season. These results reinforce the benefits of COVID-19 vaccination and underscore the importance of remaining up to date with vaccine recommendations.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR154
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Infectious Disease (non-vaccine), STA: Vaccines